{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:12:45Z","timestamp":1776273165008,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,9,30]],"date-time":"2015-09-30T00:00:00Z","timestamp":1443571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,9,30]],"date-time":"2015-09-30T00:00:00Z","timestamp":1443571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1038\/leu.2015.259","type":"journal-article","created":{"date-parts":[[2015,9,30]],"date-time":"2015-09-30T06:41:26Z","timestamp":1443595286000},"page":"409-416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20"],"prefix":"10.1038","volume":"30","author":[{"given":"B Dalla","family":"Palma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Guasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Pedrazzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Bolzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Accardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Sammarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Craviotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"De Filippo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Ruffini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Omed\u00e8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Ria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Aversa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,30]]},"reference":[{"issue":"Suppl 2","key":"BFleu2015259_CR1","first-page":"3","volume":"25","author":"KC Anderson","year":"2011","unstructured":"Anderson KC . Multiple myeloma: a clinical overview. Oncology (Williston Park) 2011; 25 (Suppl 2): 3\u20139.","journal-title":"Oncology (Williston Park)"},{"key":"BFleu2015259_CR2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/bjh.12007","volume":"159","author":"E Zamagni","year":"2012","unstructured":"Zamagni E, Cavo M . The role of imaging techniques in the management of multiple myeloma. Br J Haematol 2012; 159: 499\u2013513.","journal-title":"Br J Haematol"},{"key":"BFleu2015259_CR3","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.3109\/10428194.2011.573036","volume":"52","author":"E Tan","year":"2011","unstructured":"Tan E, Weiss BM, Mena E, Korde N, Choyke PL, Landgren O . Current and future imaging modalities for multiple myeloma and its precursor states. Leuk Lymphoma 2011; 52: 1630\u20131640.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2015259_CR4","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1200\/JCO.2014.57.9961","volume":"33","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol 2015; 33: 657\u2013664.","journal-title":"J Clin Oncol"},{"key":"BFleu2015259_CR5","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1016\/j.ejrad.2014.09.012","volume":"83","author":"C Mesguich","year":"2014","unstructured":"Mesguich C, Fardanesh R, Tanenbaum L, Chari A, Jagannath S, Kostakoglu L . State of the art imaging of multiple myeloma: comparative review of FDG PET\/CT imaging in various clinical settings. Eur J Radiol 2014; 83: 2203\u20132223.","journal-title":"Eur J Radiol"},{"key":"BFleu2015259_CR6","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15: e538\u2013e548.","journal-title":"Lancet Oncol"},{"key":"BFleu2015259_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/leu.2008.336","volume":"23","author":"GD Roodman","year":"2009","unstructured":"Roodman GD . Pathogenesis of myeloma bone disease. Leukemia 2009; 23: 435\u2013441.","journal-title":"Leukemia"},{"key":"BFleu2015259_CR8","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","volume":"98","author":"N Giuliani","year":"2001","unstructured":"Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S . Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001; 98: 3527\u20133533.","journal-title":"Blood"},{"key":"BFleu2015259_CR9","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1056\/NEJMoa030847","volume":"349","author":"E Tian","year":"2003","unstructured":"Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483\u20132494.","journal-title":"N Engl J Med"},{"key":"BFleu2015259_CR10","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1073\/pnas.0911929107","volume":"107","author":"S Vallet","year":"2010","unstructured":"Vallet S, Mukherjee S, Vaghela N, Hideshima T, Fulciniti M, Pozzi S et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci USA 2010; 107: 5124\u20135129.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2015259_CR11","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/leu.2013.385","volume":"28","author":"R Silbermann","year":"2014","unstructured":"Silbermann R, Bolzoni M, Storti P, Guasco D, Bonomini S, Zhou D et al. Bone marrow monocyte-\/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma. Leukemia 2014; 28: 951\u2013954.","journal-title":"Leukemia"},{"key":"BFleu2015259_CR12","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1182\/blood-2005-03-1080","volume":"106","author":"LA Ehrlich","year":"2005","unstructured":"Ehrlich LA, Chung HY, Ghobrial I, Choi SJ, Morandi F, Colla S et al. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 2005; 106: 1407\u20131414.","journal-title":"Blood"},{"key":"BFleu2015259_CR13","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1182\/blood-2003-06-1992","volume":"103","author":"JW Lee","year":"2004","unstructured":"Lee JW, Chung HY, Ehrlich LA, Jelinek DF, Callander NS, Roodman GD et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 2004; 103: 2308\u20132315.","journal-title":"Blood"},{"key":"BFleu2015259_CR14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood.V96.2.671","volume":"96","author":"SJ Choi","year":"2000","unstructured":"Choi SJ, Cruz JC, Craig F, Chung H, Devlin RD, Roodman GD et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000; 96: 671\u2013675.","journal-title":"Blood"},{"key":"BFleu2015259_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1046\/j.1365-2141.2003.04040.x","volume":"120","author":"S Uneda","year":"2003","unstructured":"Uneda S, Hata H, Matsuno F, Harada N, Mitsuya Y, Kawano F et al. Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br J Haematol 2003; 120: 53\u201355.","journal-title":"Br J Haematol"},{"key":"BFleu2015259_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1365-2141.2004.04864.x","volume":"125","author":"T Hashimoto","year":"2004","unstructured":"Hashimoto T, Abe M, Oshima T, Shibata H, Ozaki S, Inoue D et al. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol 2004; 125: 38\u201341.","journal-title":"Br J Haematol"},{"key":"BFleu2015259_CR17","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1182\/blood-2010-05-283895","volume":"116","author":"K Noonan","year":"2010","unstructured":"Noonan K, Marchionni L, Anderson J, Pardoll D, Roodman GD, Borrello I . A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 2010; 116: 3554\u20133563.","journal-title":"Blood"},{"key":"BFleu2015259_CR18","doi-asserted-by":"publisher","first-page":"6840","DOI":"10.1158\/0008-5472.CAN-08-0402","volume":"68","author":"N Giuliani","year":"2008","unstructured":"Giuliani N, Lisignoli G, Colla S, Lazzaretti M, Storti P, Mancini C et al. CC-chemokine ligand 20\/macrophage inflammatory protein-3alpha and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions. Cancer Res 2008; 68: 6840\u20136850.","journal-title":"Cancer Res"},{"key":"BFleu2015259_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1056\/NEJM200407083510223","volume":"351","author":"DF Robbiani","year":"2004","unstructured":"Robbiani DF, Chesi M, Bergsagel PL . Bone lesions in molecular subtypes of multiple myeloma. N Engl J Med 2004; 351: 197\u2013198.","journal-title":"N Engl J Med"},{"key":"BFleu2015259_CR20","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/leu.2010.173","volume":"24","author":"E Terpos","year":"2010","unstructured":"Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescio R et al. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia 2010; 24: 1700\u20131712.","journal-title":"Leukemia"},{"key":"BFleu2015259_CR21","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","volume":"102","author":"E Terpos","year":"2003","unstructured":"Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003; 102: 1064\u20131069.","journal-title":"Blood"},{"key":"BFleu2015259_CR22","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3324\/haematol.10943","volume":"92","author":"V Goranova-Marinova","year":"2007","unstructured":"Goranova-Marinova V, Goranov S, Pavlov P, Tzvetkova T . Serum levels of OPG, RANKL and RANKL\/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations. Haematologica 2007; 92: 1000\u20131001.","journal-title":"Haematologica"},{"key":"BFleu2015259_CR23","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3816\/CLM.2009.n.085","volume":"9","author":"C Jakob","year":"2009","unstructured":"Jakob C, Goerke A, Terpos E, Sterz J, Heider U, Kuhnhardt D et al. Serum levels of total-RANKL in multiple myeloma. Clin Lymphoma Myeloma 2009; 9: 430\u2013435.","journal-title":"Clin Lymphoma Myeloma"},{"key":"BFleu2015259_CR24","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/j.1600-0609.2008.01065.x","volume":"80","author":"M Kaiser","year":"2008","unstructured":"Kaiser M, Mieth M, Liebisch P, Oberlander R, Rademacher J, Jakob C et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol 2008; 80: 490\u2013494.","journal-title":"Eur J Haematol"},{"key":"BFleu2015259_CR25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1046\/j.1365-2141.2003.04561.x","volume":"123","author":"E Terpos","year":"2003","unstructured":"Terpos E, Politou M, Szydlo R, Goldman JM, Apperley JF, Rahemtulla A . Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol 2003; 123: 106\u2013109.","journal-title":"Br J Haematol"},{"key":"BFleu2015259_CR26","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.exphem.2010.06.012","volume":"38","author":"Y Cao","year":"2010","unstructured":"Cao Y, Luetkens T, Kobold S, Hildebrandt Y, Gordic M, Lajmi N et al. The cytokine\/chemokine pattern in the bone marrow environment of multiple myeloma patients. Exp Hematol 2010; 38: 860\u2013867.","journal-title":"Exp Hematol"},{"key":"BFleu2015259_CR27","first-page":"800","volume":"85","author":"F Di Raimondo","year":"2000","unstructured":"Di Raimondo F, Azzaro MP, Palumbo G, Bagnato S, Giustolisi G, Floridia P et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 2000; 85: 800\u2013805.","journal-title":"Haematologica"},{"key":"BFleu2015259_CR28","first-page":"454","volume":"53","author":"M Kraj","year":"2005","unstructured":"Kraj M, Owczarska K, Sokolowska U, Centkowski P, Poglod R, Kruk B . Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients. Arch Immunol Ther Exp (Warsz) 2005; 53: 454\u2013464.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"BFleu2015259_CR29","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","volume":"28","author":"A Palumbo","year":"2010","unstructured":"Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010; 28: 5101\u20135109.","journal-title":"J Clin Oncol"},{"key":"BFleu2015259_CR30","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3324\/haematol.2013.091918","volume":"99","author":"J Caers","year":"2014","unstructured":"Caers J, Withofs N, Hillengass J, Simoni P, Zamagni E, Hustinx R et al. The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma. Haematologica 2014; 99: 629\u2013637.","journal-title":"Haematologica"},{"key":"BFleu2015259_CR31","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","volume":"118","author":"E Zamagni","year":"2011","unstructured":"Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A et al. Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 2011; 118: 5989\u20135995.","journal-title":"Blood"},{"key":"BFleu2015259_CR32","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1182\/blood-2012-08-451690","volume":"121","author":"SZ Usmani","year":"2013","unstructured":"Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood 2013; 121: 1819\u20131823.","journal-title":"Blood"},{"key":"BFleu2015259_CR33","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/leu.2013.258","volume":"28","author":"AJ Greenberg","year":"2014","unstructured":"Greenberg AJ, Rajkumar SV, Therneau TM, Singh PP, Dispenzieri A, Kumar SK . Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. Leukemia 2014; 28: 398\u2013403.","journal-title":"Leukemia"},{"key":"BFleu2015259_CR34","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/j.1365-2141.2004.05092.x","volume":"126","author":"M Politou","year":"2004","unstructured":"Politou M, Terpos E, Anagnostopoulos A, Szydlo R, Laffan M, Layton M et al. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2004; 126: 686\u2013689.","journal-title":"Br J Haematol"},{"key":"BFleu2015259_CR35","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1182\/blood.V98.7.2269","volume":"98","author":"C Seidel","year":"2001","unstructured":"Seidel C, Hjertner O, Abildgaard N, Heickendorff L, Hjorth M, Westin J et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 2001; 98: 2269\u20132271.","journal-title":"Blood"},{"key":"BFleu2015259_CR36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.humimm.2008.01.006","volume":"69","author":"P Schutt","year":"2008","unstructured":"Schutt P, Rebmann V, Brandhorst D, Wiefelsputz J, Ebeling P, Opalka B et al. The clinical significance of soluble human leukocyte antigen class-I, ICTP, and RANKL molecules in multiple myeloma patients. Hum Immunol 2008; 69: 79\u201387.","journal-title":"Hum Immunol"},{"key":"BFleu2015259_CR37","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1080\/10428190701648281","volume":"48","author":"N Giuliani","year":"2007","unstructured":"Giuliani N, Rizzoli V . Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma. Leuk Lymphoma 2007; 48: 2323\u20132329.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2015259_CR38","doi-asserted-by":"publisher","first-page":"867576","DOI":"10.1155\/2011\/867576","volume":"2011","author":"K Sfiridaki","year":"2011","unstructured":"Sfiridaki K, Pappa CA, Tsirakis G, Kanellou P, Kaparou M, Stratinaki M et al. Angiogenesis-related cytokines, RANKL, and osteoprotegerin in multiple myeloma patients in relation to clinical features and response to treatment. Mediators Inflamm 2011; 2011: 867576.","journal-title":"Mediators Inflamm"},{"key":"BFleu2015259_CR39","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1038\/sj.leu.2403423","volume":"18","author":"E Terpos","year":"2004","unstructured":"Terpos E, Politou M, Szydlo R, Nadal E, Avery S, Olavarria E et al. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL\/osteoprotegerin ratio in patients with multiple myeloma. Leukemia 2004; 18: 1420\u20131426.","journal-title":"Leukemia"},{"key":"BFleu2015259_CR40","first-page":"2306","volume":"8","author":"A Lipton","year":"2002","unstructured":"Lipton A, Ali SM, Leitzel K, Chinchilli V, Witters L, Engle L et al. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 2002; 8: 2306\u20132310.","journal-title":"Clin Cancer Res"},{"key":"BFleu2015259_CR41","doi-asserted-by":"publisher","first-page":"7665","DOI":"10.1158\/0008-5472.CAN-06-4666","volume":"67","author":"N Giuliani","year":"2007","unstructured":"Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Donofrio G, Bonomini S et al. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res 2007; 67: 7665\u20137674.","journal-title":"Cancer Res"},{"key":"BFleu2015259_CR42","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","volume":"135","author":"E Terpos","year":"2006","unstructured":"Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006; 135: 688\u2013692.","journal-title":"Br J Haematol"},{"key":"BFleu2015259_CR43","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1177\/0022034513500306","volume":"92","author":"BF Boyce","year":"2013","unstructured":"Boyce BF . Advances in the regulation of osteoclasts and osteoclast functions. J Dent Res 2013; 92: 860\u2013867.","journal-title":"J Dent Res"},{"key":"BFleu2015259_CR44","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cellimm.2013.06.001","volume":"285","author":"W Qi","year":"2013","unstructured":"Qi W, Huang X, Wang J . Correlation between Th17 cells and tumor microenvironment. Cell Immunol 2013; 285: 18\u201322.","journal-title":"Cell Immunol"},{"key":"BFleu2015259_CR45","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1182\/blood-2008-03-143222","volume":"112","author":"KM Dhodapkar","year":"2008","unstructured":"Dhodapkar KM, Barbuto S, Matthews P, Kukreja A, Mazumder A, Vesole D et al. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 2008; 112: 2878\u20132885.","journal-title":"Blood"},{"key":"BFleu2015259_CR46","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1084\/jem.20030137","volume":"197","author":"NE Annels","year":"2003","unstructured":"Annels NE, Da Costa CE, Prins FA, Willemze A, Hogendoorn PC, Egeler RM . Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis. J Exp Med 2003; 197: 1385\u20131390.","journal-title":"J Exp Med"},{"key":"BFleu2015259_CR47","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/00062752-199801000-00010","volume":"5","author":"S Ladisch","year":"1998","unstructured":"Ladisch S . Langerhans cell histiocytosis. Curr Opin Hematol 1998; 5: 54\u201358.","journal-title":"Curr Opin Hematol"},{"key":"BFleu2015259_CR48","doi-asserted-by":"publisher","first-page":"e58504","DOI":"10.1371\/journal.pone.0058504","volume":"8","author":"MM Zheng","year":"2013","unstructured":"Zheng MM, Zhang Z, Bemis K, Belch AR, Pilarski LM, Shively JE et al. The systemic cytokine environment is permanently altered in multiple myeloma. PLoS One 2013; 8: e58504.","journal-title":"PLoS One"},{"key":"BFleu2015259_CR49","doi-asserted-by":"publisher","first-page":"4615","DOI":"10.1182\/blood-2002-04-1121","volume":"100","author":"N Giuliani","year":"2002","unstructured":"Giuliani N, Colla S, Sala R, Moroni M, Lazzaretti M, La Monica S et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 2002; 100: 4615\u20134621.","journal-title":"Blood"},{"key":"BFleu2015259_CR50","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1182\/blood-2005-07-2719","volume":"107","author":"N Giuliani","year":"2006","unstructured":"Giuliani N, Morandi F, Tagliaferri S, Colla S, Bonomini S, Sammarelli G et al. Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients. Blood 2006; 107: 841\u2013842.","journal-title":"Blood"},{"key":"BFleu2015259_CR51","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/leu.2011.43","volume":"25","author":"S Vallet","year":"2011","unstructured":"Vallet S, Pozzi S, Patel K, Vaghela N, Fulciniti MT, Veiby P et al. A novel role for CCL3 (MIP-1alpha) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia 2011; 25: 1174\u20131181.","journal-title":"Leukemia"},{"key":"BFleu2015259_CR52","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.leukres.2014.02.010","volume":"38","author":"XT Wang","year":"2014","unstructured":"Wang XT, He YC, Zhou SY, Jiang JZ, Huang YM, Liang YZ et al. Bone marrow plasma macrophage inflammatory protein protein-1 alpha(MIP-1 alpha) and sclerostin in multiple myeloma: relationship with bone disease and clinical characteristics. Leuk Res 2014; 38: 525\u2013531.","journal-title":"Leuk Res"},{"key":"BFleu2015259_CR53","doi-asserted-by":"publisher","first-page":"6529","DOI":"10.1182\/blood-2011-04-351437","volume":"118","author":"AC Ng","year":"2011","unstructured":"Ng AC, Khosla S, Charatcharoenwitthaya N, Kumar SK, Achenbach SJ, Holets MF et al. Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1alpha levels in patients with MGUS. Blood 2011; 118: 6529\u20136534.","journal-title":"Blood"},{"key":"BFleu2015259_CR54","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1182\/blood.V87.11.4762.bloodjournal87114762","volume":"87","author":"R Bataille","year":"1996","unstructured":"Bataille R, Chappard D, Basle MF . Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies. Blood 1996; 87: 4762\u20134769.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2015259.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015259","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015259.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T13:27:54Z","timestamp":1718112474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2015259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,30]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["BFleu2015259"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.259","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,30]]},"assertion":[{"value":"13 June 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}